Price
No data yet.
Social Signal Score
Analyst Ratings
15 analystsRevenue
$350.0KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Sanjiv K. Patel
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 202
- Beta
- 1.70
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 28.37
Financials
Revenue
$350.0K-99.6%Net Income
$-83.71MEBITDA
$-82.84MFree Cash Flow
$-54.11MEPS (diluted)
$-0.41Shares Outstanding (diluted)
202.85M+6468.1%Operating Expenses
$91.17MCash & Debt
$910.93MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $15.36M | $-276.48M | $-1.61 |
| 2024 | $10.01M | $-337.71M | $-2.36 |
| 2023 | $25.55M | $-341.97M | $-2.79 |
| 2022 | $1.38M | $-290.51M | $-2.59 |
| 2021 | $3.03M | $-363.87M | $-3.82 |
| 2020 | $82.65M | $-52.41M | $-2.56 |
| 2019 | $0.00 | $-66.50M | $-15.53 |
| 2018 | $0.00 | $-48.78M | $-19.63 |
Valuation
RLAYhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+20.00%Social Signal Score
Mentions (4)
- Newsseekingalpha.com·19d ago·Positive
Relay Therapeutics, Inc. (RLAY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Relay Therapeutics, Inc. (RLAY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·26d ago·Neutral
Relay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript Relay Therapeutics, Inc. (RLAY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Transcript
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in September:
View source ↗ - 4chan /biz/biz·64d ago·Neutral
>>62553499 How otherwise do you think disabling Replace-By-Fee (RBF) works than? The race. Thousands of at-risk wallets need to be swept to fresh seeds over the coming days and weeks. For each of them there is exactly one dangerous window: the time between the sweep transaction hitting the mempool and it confirming in a block. During that window, an attacker holding the keys can broadcast a conflicting transaction paying a higher fee and redirect everything. A miner running full-RBF will happi
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.40 per share
Typical surprise +8.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.41 vs $-0.39miss
- Tue, May 5$-0.41 vs $-0.35miss
- Thu, Feb 26$-0.32 vs $-0.38beat
- Thu, Nov 6$-0.43 vs $-0.39miss
- Thu, Aug 7$-0.41 vs $-0.49beat
- Mon, May 5$-0.46 vs $-0.50beat
Estimates and results for RLAY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RLAY officers and directors.
- Bought
- —
- Sold
- $128.0m
0 trades
61 trades
- Bergstrom Donald Asold
- Catinazzo Thomassold
- Patel Sanjivsold
- Rahmer Petersold
- Svf Pauling (cayman) Ltdsold
- Patel Sanjivsold
- Catinazzo Thomassold
- Catinazzo Thomassold
39 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (32d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.